Company Provides Details on 2008 Annual Meeting of Stockholders
VALLEY FORGE, Pa.--(BUSINESS WIRE)--Jan. 21,
2008--AmerisourceBergen (NYSE:ABC) today began mailing its "Notice of
Internet Availability of Proxy Materials" for its 2008 Annual Meeting
of Stockholders under the new Notice and Access rule of the U.S.
Securities and Exchange Commission (SEC).
AmerisourceBergen is among the first large accelerated filers to
implement the SEC's new Notice and Access rule. The rule allows
companies to furnish proxy materials to stockholders via the Internet
as an alternative to the traditional approach of delivering a printed
set to each stockholder. The proxy statement for the 2008 annual
meeting, stockholder letter and the 2007 Annual Report on Form 10-K as
filed with the SEC for the fiscal year ended September 30, 2007 are
available on the 2008 Proxy Materials page in the Investor Relations
section of www.amerisourcebergen.com. AmerisourceBergen stockholders
also may obtain hard copies of the Company's proxy materials for the
2008 annual meeting free of charge by following the instructions
provided in the "Notice of Internet Availability of Proxy Materials"
that was mailed to stockholders on or about January 18, 2008.
The Company's Annual Meeting of Stockholders will be held on
February 28, 2008 at 2:00 pm Eastern Time at The Four Seasons Hotel in
Philadelphia, Pennsylvania.
About AmerisourceBergen
AmerisourceBergen is one of the world's largest pharmaceutical
services companies serving primarily the United States and Canada.
Servicing both pharmaceutical manufacturers and healthcare providers
in the pharmaceutical supply channel, the Company provides drug
distribution and related services designed to reduce costs and improve
patient outcomes. AmerisourceBergen's service solutions range from
pharmacy automation and pharmaceutical packaging to reimbursement and
pharmaceutical consulting services. With more than $66 billion in
annual revenue, AmerisourceBergen is headquartered in Valley Forge,
PA, and employs more than 11,500 people. AmerisourceBergen is ranked
#29 on the Fortune 500 list. For more information, go to
www.amerisourcebergen.com.
Forward-Looking Statements
This news release may contain certain "forward-looking statements"
within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. These statements
are based on management's current expectations and are subject to
uncertainty and changes in circumstances. Actual results may vary
materially from the expectations contained in the forward-looking
statements. The following factors, among others, could cause actual
results to differ materially from those described in any
forward-looking statements: competitive pressures; the loss of one or
more key customer or supplier relationships; customer defaults or
insolvencies; changes in customer mix; supplier defaults or
insolvencies; changes in pharmaceutical manufacturers' pricing and
distribution policies or practices; adverse resolution of any contract
or other disputes with customers (including departments and agencies
of the U.S. Government) or suppliers; regulatory changes (including
increased government regulation of the pharmaceutical supply channel);
government enforcement initiatives (including (i) the imposition of
increased obligations upon pharmaceutical distributors to detect and
prevent suspicious orders of controlled substances, (ii) the
commencement of further administrative actions by the U. S. Drug
Enforcement Administration seeking to suspend or revoke the license of
any of the Company's distribution facilities to distribute controlled
substances, (iii) the commencement of any enforcement actions by any
U.S. Attorney alleging violation of laws and regulations regarding
diversion of controlled substances and suspicious order monitoring, or
(iv) the commencement of any administrative actions by the board of
pharmacy of any state seeking to suspend, revoke or otherwise restrict
the ability of any of the Company's distribution facilities or
businesses to distribute or dispense pharmaceuticals in such state);
changes in U.S. government policies (including reimbursement changes
arising from federal legislation, including the Medicare Modernization
Act and the Deficit Reduction Act of 2005); changes in regulatory or
clinical medical guidelines and/or reimbursement practices for the
pharmaceuticals we distribute, including erythropoiesis-stimulating
agents (ESAs) used to treat anemia patients; price inflation in
branded pharmaceuticals and price deflation in generics; the inability
of the Company to successfully complete any transaction that the
Company may wish to pursue from time to time; fluctuations in market
interest rates; operational or control issues arising from the
Company's outsourcing of information technology activities; success of
integration, restructuring or systems initiatives; fluctuations in the
U.S. dollar - Canadian dollar exchange rate and other foreign exchange
rates; economic, business, competitive and/or regulatory developments
in Canada, the United Kingdom and elsewhere outside of the United
States; acquisition of businesses that do not perform as we expect or
that are difficult for us to integrate or control; any operating
problems and/or cost overruns that may be associated with the
implementation of an enterprise resource planning system; changes in
tax legislation or adverse resolution of challenges to our tax
positions; and other economic, business, competitive, legal, tax,
regulatory and/or operational factors affecting the business of the
Company generally. Certain additional factors that management believes
could cause actual outcomes and results to differ materially from
those described in forward-looking statements are set forth (i) in
Item 1A (Risk Factors) in the Company's Annual Report on Form 10-K for
the fiscal year ended September 30, 2007 and elsewhere in that report
and (ii) in other reports filed by the Company pursuant to the
Securities Exchange Act of 1934.
CONTACT: AmerisourceBergen
Michael N. Kilpatric, 610-727-7118
mkilpatric@amerisourcebergen.com
SOURCE: AmerisourceBergen